MAGE A3 antigen-specific cancer immunotherapeutic

被引：56

作者：

Peled, Nir ^{[1
]}

Oton, Ana B. ^{[1
]}

Hirsch, Fred R. ^{[1
]}

Bunn, Paul ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA

来源：

IMMUNOTHERAPY | 2009年 / 1卷 / 01期

关键词：

MAGE; melanoma; non-small-cell lung cancer; NSCLC; vaccine; T-CELL RESPONSES; LUNG-CANCER; GENES; PROTEIN; EXPRESSION; MELANOMA; EPITOPES; IDENTIFICATION; IMMUNIZATION; VACCINATION;

D O I：

10.2217/1750743X.1.1.19

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Non-small-cell lung cancer (NSCLC) and melanoma are devastating diseases with high rates of recurrence. Current clinical recommendations include postoperative adjuvant chemotherapy in stages 11 and IIIA NSCLC, while there is a debate regarding its clinical benefit in stage IB. Recent Phase 11 trials have demonstrated a clinical benefit by postoperative vaccine with melanoma-specific antigen A3 (MAGE A3) in NSCLC and in stage IV melanoma. These trials have led to the current Phase III trials. MAGE A3 is a tumor-specific shared antigen that is frequently expressed in lung cancer and melanoma, as well as in few other tumors. Its level is associated with disease burden and with prognosis, while normal tissues do not express it, except the testis and the placenta. This review will summarize the recent developments and clinical experience with the MAGE A3 vaccine.

引用

页码：19 / 25

页数：7

共 41 条

[1] BCG immunotherapy of bladder cancer: 20 years on [J].

Alexandroff, AB ;

Jackson, AM ;

O'Donnell, MA ;

James, K .

LANCET, 1999, 353 (9165) :1689-1694

[2]

[Anonymous], [No title captured]

[3] Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients [J].

Atanackovic, D ;

Altorki, NK ;

Stockert, E ;

Williamson, B ;

Jungbluth, AA ;

Ritter, E ;

Santiago, D ;

Ferrara, CA ;

Matsuo, M ;

Selvakumar, A ;

Dupont, B ;

Chen, YT ;

Hoffman, EW ;

Ritter, G ;

Old, LJ ;

Gnjatic, S .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3289-3296

[4] Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming [J].

Atanackovic, Djordje ;

Altorki, Nasser K. ;

Cao, Yanran ;

Ritter, Erika ;

Ferrara, Cathy A. ;

Ritter, Gerd ;

Hoffman, Eric W. ;

Bokemeyer, Carsten ;

Old, Lloyd J. ;

Gnjatic, Sacha .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1650-1655

[5] BAGE - A NEW GENE ENCODING AN ANTIGEN RECOGNIZED ON HUMAN MELANOMAS BY CYTOLYTIC T-LYMPHOCYTES [J].

BOEL, P ;

WILDMANN, C ;

SENSI, ML ;

BRASSEUR, R ;

RENAULD, JC ;

COULIE, P ;

BOON, T ;

VANDERBRUGGEN, P .

IMMUNITY, 1995, 2 (02) :167-175

[6] Immunotherapy for lung cancer [J].

Bradbury, Penelope A. ;

Shepherd, Frances A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) :S164-S170

[7] EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA [J].

BRASSEUR, F ;

RIMOLDI, D ;

LIENARD, D ;

LETHE, B ;

CARREL, S ;

ARIENTI, F ;

SUTER, L ;

VANWIJCK, R ;

BOURLOND, A ;

HUMBLET, Y ;

VACCA, A ;

CONESE, M ;

LAHAYE, T ;

DEGIOVANNI, G ;

DERAEMAECKER, R ;

BEAUDUIN, M ;

SASTRE, X ;

SALAMON, E ;

DRENO, B ;

JAGER, E ;

KNUTH, A ;

CHEVREAU, C ;

SUCIU, S ;

LACHAPELLE, JM ;

POUILLART, P ;

PARMIANI, G ;

LEJEUNE, F ;

CEROTTINI, JC ;

BOON, T ;

MARCHAND, M .

INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (03) :375-380

[8] HUMAN GENE MAGE-1, WHICH CODES FOR A TUMOR-REJECTION ANTIGEN, IS EXPRESSED BY SOME BREAST-TUMORS [J].

BRASSEUR, F ;

MARCHAND, M ;

VANWIJCK, R ;

HERIN, M ;

LETHE, B ;

CHOMEZ, P ;

BOON, T .

INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (05) :839-841

[9] Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy [J].

Bredenbeck, A ;

Losch, FO ;

Sharav, T ;

Eichler-Mertens, M ;

Filter, M ;

Givehchi, A ;

Sterry, W ;

Wrede, P ;

Walden, P .

JOURNAL OF IMMUNOLOGY, 2005, 174 (11) :6716-6724

[10] GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development [J].

Brichard, Vincent G. ;

Lejeune, Diane .

VACCINE, 2007, 25 :B61-B71

← 1 2 3 4 5 →